Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genocea Biosciences (GNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,511
  • Shares Outstanding, K 82,100
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,710 K
  • 36-Month Beta 1.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.85 +18.24%
on 02/06/18
1.08 -6.94%
on 02/07/18
+0.12 (+12.92%)
since 01/19/18
3-Month
0.79 +27.22%
on 01/17/18
1.39 -27.70%
on 12/27/17
-0.15 (-13.36%)
since 11/21/17
52-Week
0.79 +27.22%
on 01/17/18
7.29 -86.21%
on 04/25/17
-3.73 (-78.80%)
since 02/21/17

Most Recent Stories

More News
Genocea Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 15, 2018 / Genocea Biosciences, Inc. (NASDAQ: GNCA) will be discussing their earnings results in their Q4 Earnings Call to be held on February 15, 2018, at 9:00 AM...

GNCA : 1.00 (unch)
NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences' Board of Directors

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Ali Behbahani, M.D., a partner in the healthcare group at New Enterprise...

GNCA : 1.00 (unch)
Genocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announced today that it intends to offer and sell in concurrent underwritten public...

GNCA : 1.00 (unch)
Factors of Influence in 2018, Key Indicators and Opportunity within Kelly Services, Genocea Biosciences, Balchem, Federal Signal, Marriott Vacations Worldwide, and International Bancshares -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kelly Services, Inc. (NASDAQ:KELYA),...

GNCA : 1.00 (unch)
FSS : 19.60 (+0.93%)
VAC : 143.46 (+0.48%)
KELYB : 29.00 (-0.24%)
KELYA : 30.24 (+2.79%)
BCPC : 74.85 (-0.05%)
IBOC : 40.90 (+1.36%)
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Genocea Biosciences, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018

NEW YORK, NY / ACCESSWIRE / December 28, 2017 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Genocea Biosciences, Inc. (NASDAQ: GNCA) who purchased...

GNCA : 1.00 (unch)
Robbins Arroyo LLP: Genocea Biosciences, Inc. (GNCA) Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that investors filed a securities class action complaint against Genocea Biosciences, Inc. (Nasdaq: GNCA) on behalf of all purchasers...

GNCA : 1.00 (unch)
Scott+Scott, Attorneys at Law, LLP Reminds Investors that the Lead Plaintiff Deadline in Genocea Biosciences, Inc. (GNCA) Class Action is January 2nd

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is reminding investors that a class action has been filed against Genocea...

GNCA : 1.00 (unch)
GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the District of Massachusetts on behalf...

GNCA : 1.00 (unch)
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline - January 2, 2018

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Genocea Bioscience, Inc. (''Genocea'' or the ''Company'')...

GNCA : 1.00 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Genocea Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline - GNCA

Pomerantz LLP announces that a class action lawsuit has been filed against Genocea Biosciences, Inc. ("Genocea" or the "Company") (NASDAQ:GNCA) and certain of its officers. The class action, filed in...

GNCA : 1.00 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections,...

See More

Key Turning Points

2nd Resistance Point 1.04
1st Resistance Point 1.02
Last Price 1.00
1st Support Level 0.99
2nd Support Level 0.97

See More

52-Week High 7.29
Fibonacci 61.8% 4.81
Fibonacci 50% 4.04
Fibonacci 38.2% 3.27
Last Price 1.00
52-Week Low 0.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.